Liuliang Qin (LiuLiang Qin)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Diffusion Weighted

Circulating Tumor

Metastatic Breast Cancer

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, Natalya D Bodyak, Shuyi Tang, Marina Protopopova, Eugene Kelleher, Brian Jones, Liping Yang, Daniel Custar, Kalli C Catcott, Damon R Demady, Scott D Collins, Ling Xu, Charlie Bu, Liuliang Qin, Elena Ter-Ovanesyan, Marc Damelin, Dorin Toader, Timothy B Lowinger
Development of a Novel DNA Mono-alkylator Platform for Antibody Drug Conjugates. Molecular cancer therapeutics (2024)
Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, Natalya D Bodyak, Shuyi Tang, Marina Protopopova, Eugene Kelleher, Brian Jones, Liping Yang, Daniel Custar, Kalli C Catcott, Damon R Demady, Scott D Collins, Ling Xu, Charlie Bu, Liuliang Qin, Elena Ter-Ovanesyan, Marc Damelin, Dorin Toader, Timothy B Lowinger
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. Molecular cancer therapeutics 23 (4) (2024)
Dorin Toader, Shawn P Fessler, Scott D Collins, Patrick R Conlon, Reddy Bollu, Kalli C Catcott, Chen-Ni Chin, Anouk Dirksen, Bingfan Du, Jeremy R Duvall, Stacy Higgins, Mariya V Kozytska, Kamela Bellovoda, Chelsey Faircloth, David H Lee, Fu Li, Liuliang Qin, Caitlin Routhier, Pamela Shaw, Cheri A Stevenson, Jason Wang, Phonphimon Wongthida, Elena Ter-Ovanesyan, Elizabeth Ditty, Stephen P Bradley, Ling Xu, Mao Yin, Aleksandr V Yurkovetskiy, Rebecca Mosher, Marc Damelin, Timothy B Lowinger
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Molecular cancer therapeutics (2023)
Susan M Clardy, Alex Uttard, Bingfan Du, Kalli C Catcott, Kelly L Lancaster, Elizabeth Ditty, Jack Sadowsky, Jeffrey Zurita, Naniye Malli Cetinbas, Liuliang Qin, Stephen P Bradley, Kenneth Avocetien, Tyler Carter, Dokyong Kim, Mark Nazzaro, Ling Xu, Thomas H Pillow, Neelie T Zacharias, Gail D Lewis Phillips, Rebecca K Rowntree, Radha Iyengar, David H Lee, Marc Damelin, Dorin Toader, Timothy B Lowinger
Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios. Molecular cancer therapeutics (2023)